Rhabdomyosarcoma Therapeutics Analysis and Developments

Rhabdomyosarcoma (RMS) Therapeutics currently exhibits a proliferating pipeline with 5+ therapeutic candidates.

Rhabdomyosarcoma (RMS) is a type of cancer that usually affects children. Soft tissues or hollow organs such as bladder or uterus are often affected by this disease. There are mainly two types of RMS: embryonal RMS (ERMS) and alveolar RMS (ARMS). Other types include anaplastic RMS and undifferentiated sarcoma. Depending on the type, RMS is likely to affect head and neck area, vagina, urinary bladder, uterus or testes, arms, and legs. There are certain risk factors associated with the disease, such as genetic disorders, including Li-Fraumeni syndrome, neurofibromatosis, Beckwith-Wiedemann syndrome, and Costello syndrome.

According to the research findings, majority of pipeline drug candidates are being developed for intravenous route of administration. In this route of administration, entire administered dose reaches the systemic circulation immediately, which increases the bioavailability of drug.

Cosmegen and VinCRIStine Sulfate are approved drugs for the treatment of RMS. Moreover, with the emergence of late- and mid-stage pipeline products in the market, the overall RMS therapeutic market is expected to rise significantly in the upcoming years.

Taiwan Liposome Company Ltd., Ovation Pharmaceuticals Inc., Hospira Inc., F. Hoffmann-La Roche Ltd., Epizyme Inc., and Novartis AG are some of the significant players involved in the development of RMS therapeutics.

Read more: https://www.pharmaproff.com/report/rms-therapeutics-pipeline-analysis